Introduction
drome. 2 Mucopolysaccharidosis type 1 (MPS 1), the most freAlthough a complete genotype-phenotype correlation quently occurring MPS, is an autosomal recessive disease for mutations of the gene encoding ␣-(l)-iduronidase has due to mutations in the gene encoding ␣-(l)- iduronidase .
not yet been established, some nonsense mutations which The gene defect causes a specific lysosomal enzyme correlate with the most severe Hurler's disease phenodeficiency that results in the intracellular accumulation type have been identified (mutations W402X and Q70X). 3 and storage of unprocessed glycosaminoglycans (GAGS), Establishing a complete genotype-phenotype correlation dermatan sulfate and heparan sulfate. Patients suffering should greatly aid in the accurate implementation of therfrom MPS 1 show variable clinical manifestations, the apies like bone marrow transplantation (BMT), since the most severe of which is Hurler's syndrome, with progenotype will help in the decision on whether a partigressive neurological dysfunction, skeletal and soft tissue cular patient ought to be treated by complex treatments deformities, and leading to death within the first decade.
like BMT or gene therapy. In less severe forms of this deficiency, such as the inter-BMT is used clinically to treat children suffering from mediate Hurler-Sheie syndrome, or the mild Scheie synvarious inherited lysosomal enzyme disorders, such as drome, no mental retardation and only milder symptoms the mucopolysaccharidoses and the leukodystrophies. occur. 1 Importantly, the levels of ␣-(l)-iduronidase While BMT during the very early stages of the disease enzyme remaining are inversely correlated with lysosohas been shown to reverse the peripheral (eg liver and mal distension of neurons and CNS functional deteriospleen) pathology (ie the accumulation of unmetabolized ration; ie severe distension in the neurons of patients intermediary metabolites), the effectiveness of this treatsuffering from the Hurler syndrome, and little if any in ment for preventing the progression of established neurological pathology and dysfunction remains controversial. The reversal of the peripheral lesions, however, appears Similar mechanisms of action have also been postulated to be effective in delivering enzyme activity to the central nervous system (CNS). 5 However, it is unclear whether and to what extent donor macrophages invade the host brain in human patients, and if neurons and glial cells have the capacity to take up lysosomal enzyme released into the extracellular medium.
Currently, BMT is the only therapeutic intervention for MPS-1 to have shown clinical effectiveness. 6 BMT in patients or in experimental animals can lead to correction of the enzyme defect, a decrease in abnormal lysosomes in soft tisssues, and in some cases stabilisation of the neurological status. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] However, while there is general agreement on the effectiveness of BMT for the treatment of liver, spleen or soft tissue disease, there is no consensus on whether it has a beneficial effect on the disease induced progressive deterioration of brain function. The outcome of the neurological manifestations appears to depend on the initial mental status, the age of the patient, the engraftment of the grafted bone marrow and the development of graft-versus-host diseases (GVHD). 6 So far, BMT has also been ineffective for correcting all of the skeletal abnormalities. 26 Lysosomal enzymes are post-translationally processed to contain highly phosphorylated mannose residues. These bind to mannose-6-phosphate receptors (M6P-R) which target lysosomal enzymes to lysosomes. M6P-R are also present on the cell membrane and are able to bind circulating or extracellular lysosomal enzymes and deliver them to the lysosomes; 27 ,28 these constitute the cation independent mannose 6 phosphate receptors (CI-M6P-R). Thus, lysosomal enzyme replacement was suggested for the treatment of lysosomal storage diseases, but so far has only been implemented for the treatment of Gaucher's disease. 29 The use of ␣-(l)-iduronidase enzyme and glial cells could take up ␣-(l)-iduronidase from the extracellular medium and retain it intracellularly, when ␣-(l)-iduronidase was being produced by fibroblasts Immunocytochemical distribution of the cation independent mannose-6-phosphate receptor: in primary transduced with ␣-(l)-iduronidase cDNA.
cultures of neurons, glial cells, the neuronal cell line Neuro2A and the glioma cell line C6
Results
Glial and neuronal cells were incubated with a rabbit polyclonal antibody raised against the CI-M6P-R, and all Developmental study Levels of ␣-(l)-iduronidase were examined in four brain samples tested displayed specific immunoreactivity. Primary cultures of neurons and glial cells were double areas (cortex, striatum, hippocampus and cerebellum) between embryonic day 20 and adulthood ( Figure 1) .
immunolabelled in order to identify the cell type: neurons were identified using antibodies raised against the Results were analysed statistically utilising the analysis of variance (ANOVA) and Tukey-Kramer multiple comneuron-specific protein microtubule associated protein 2 (MAP2), while glial cells were identified by their immuparison's test (for a description of the methods see Materials and methods). The statistical analysis of our noreactivity for the glial-specific intermediate filament glial fibrilary acidic protein (GFAP). Both neurons and data demonstrated that in the hippocampus, levels of ␣-(l)-iduronidase peaked between 1 and 4 days after birth, glial cells in primary cultures displayed a strong positive immunoreactivity for CI-M6P-R ( Figure 2 ). The immunoand decreased thereafter; a similar trend was seen in the cerebellum, while in the striatum and cortex, levels were reaction in neurons was stronger, and distinctly punctate when examined within the first 3 days after plating more homogenous throughout development (Figure 1 ). ( Figure 2A -C), when compared with neurons that had M6P-R immunoreactivity identified a strongly punctate structure distributed asymmetrically around the nucleus been kept in culture for 6 days, in which staining was lighter and more diffuse ( Figure 2D-F) . In glial cells, a ( Figure 4C ). Schwann cells were identified through their reactivity towards an antibody recognising the low affinstrongly punctate immunoreactive pattern was observed throughout the cytoplasm of most cells. However, variity nerve growth factor receptor (NGF-R), which is expressed by Schwann cells. In these cells CI-M6P-R ations in the pattern of immunostaining among different GFAP-positive cells could also be detected, with some immunoreactivity was distributed at low levels throughout the cells' cytoplasm ( Figure 4E-H) . GFAP immunoreactive cells displaying very low levels of reactivity with the anti CI-M6P-R antibody ( Figure 2G-I) .
Neuro2A cells displayed a lower, more diffuse immuBasal levels of ␣-(L)-iduronidase and the effects of coculture with SN6 cells or incubation with SN6 noreactivity towards the CI-M6P-R antibodies, when compared with C6 cells. The specific perinuclear fluorconditioned media The basal levels of ␣-(l)-iduronidase were 23 times escence signal was distributed asymmetrically, only occasionally demonstrating the strongly punctate pattern higher in the C6 glioma cells compared with the neuronal Neuro2A cells; and 33 times higher in the primary culseen in recently plated primary cultures of neurons ( Figure 3A-B) . In C6 glioma cells, structures immunoretures of glial cells compared with neurons in primary culture for 3-7 days. Levels of ␣-(l)-iduronidase in the priactive for CI-M6P-R displayed a punctate pattern, and positive cellular elements were distributed asymmetrimary cultures of glia were only 50% higher than in the C6 cells, and levels in primary neurons and Neuro2A cally throughout the cytoplasm, resembling a Golgi-like perinuclear pattern ( Figure 3C-D) .
cells were similar (Table 1) . Parallel cultures were incubated with normal medium (to provide basal levels of ␣-We also examined the distribution of CI-M6P-R in other putative target cells in culture, namely fibroblasts (l)-iduronidase activity), or conditioned medium, for the same amount of time, eg 3 days, and they were harvested and Schwann cells. Fibroblasts were identified by their immunoreactivity for Thy1.1, a membrane protein.
at the same time. C6 glioma cells were then incubated with SN6-conImmunostaining with a Thy1.1-specific antibody produced a fine punctate pattern compatible with its known ditioned medium as a source of lysosomal ␣-(l)-iduronidase for up to 6 days, to determine after how many days distribution on the cells' surface ( Figure 4D ), whereas CI- C6, and Neuro2A cells, primary cultures of neurons, and primary cultures of astrocytes were cultured for 3 days in SN6-conditioned incubation medium. Control cells for each cell type were maintained in unconditioned medium for the same time. After this, samples were taken for assay of enzyme activity, as described in Materials and methods. ␣-l-Iduronidase levels are given as mol/g/h. Statistically significant results are shown in the Table as of incubation in the presence of SN6-conditioned cells adopted a spindle-shaped appearance with elongated cell bodies with extended processes. The whole medium a statistically significant increase could first be detected in target cells. Intracellular levels of ␣-(l)-idupopulation of C6 cells expressed CI-M6P-R and showed a significant down-modulation of CI-M6P-R both on the ronidase were measured each day ( Figure 5 ). A statistically significant increase in the concentration of ␣-(l)-iducell membrane and in the cytoplasm. The subset of C6 cells considered negative most probably expressed an ronidase could be detected after 3 days in the presence of conditioned medium ( Figure 5 ). Thus, subsequent extremely low number of receptors below the limit of sensitivity detected by immunofluorescence and flow enzyme capture experiments were analysed following 3 days of incubation of target cells in conditioned medium.
Figure 3 Neuro2A neuroblastoma cells (A, B) and C6 glioma cells (C, D) are shown under phase contrast in A and C, and were immunoreacted with a primary anti-CI-M6P-R rabbit polyclonal antibody and a secondary antibody linked to Texas red (B and D). The Neuro2A cells (A and B) display a weak perinuclear immunopositive pattern, with some areas of punctate immunoreactivity (B). The C6 cells (C and D) when labelled with the anti-M6PR antibody, showed an asymmetric perinuclear punctate pattern of staining (D). No immunoreactivity was detected in
cytometry. Conversely, in Neuro2A cells the number of CI-M6P-R remained unchanged both on the cell memThere was a statistically significant increase in the intracellular concentration of ␣-(l)-iduronidase in all cells brane and inside the cells upon differentiation. Neuro2A differentiation was confirmed by the morphological (C6, Neuro2A, primary neuronal cultures and primary glial cultures) 3 days after incubation in 'sandwich' with change induced in the cells. SN6 cells, or at 3 days following an incubation with culture medium conditioned by SN6 cells (Table 1) . However, the data from the 'sandwich' technique were more Discussion variable than those from the incubation with conditioned medium; therefore, all of the data shown are from incuExperimental BMT studies in murine models have shown that retrovirally transduced bone marrow-derived prebations of target cells in the presence of SN6-conditioned medium. The increase of ␣-(l)-iduronidase in the target cursors of macrophages and microglial cells were able to migrate into the CNS where they can make up to 20% of cells following both types of procedures was defined as lysosomal enzyme uptake. The amount of ␣-(l)-iduronidthe total microglial population. 5 In cats suffering from ␣-mannosidosis (due to the deficiency of lysosomal ␣-ase uptake varied among cell types: C6 glioma cells, primary cultures of glia and primary cultures of neurons mannosidase) BMT was shown to prevent and also reverse lysosomal storage disease. Also, following BMT took up two to three times their basal levels of ␣-(l)-iduronidase; uptake into Neuro2A cells was higher (seven ␣-mannosidase was detected by histochemistry within brain macrophages (graft-derived) and within hostto 14 times the basal levels). derived neurons. 32 However the degree of effective enzyme replacement differed among brain regions. Brain The effect of mannose-6-phosphate and glucose-6-phosphate on ␣-(L)-iduronidase uptake autopsy analysis of clinical cases of human male-tofemale BMT have demonstrated the existence of Y chroTo determine the mechanism by which cells were able to take up ␣-(l)-iduronidase from the media, we incubated mosome-containing cells, presumed to be macrophages, within host brains by in situ hybridization utilising Y-C6 cells in the presence of conditioned medium for 3 days, in the presence of 5 mm M6P, or the structural anaspecific probes. 33 This suggests that host bone marrowderived cells appear capable of colonising the host brain logue glucose-6-phosphate. The addition of an excess of M6P, but not glucose-6-phosphate, completely blocked in animals and humans, and that BMT could thus provide platform cells to deliver lysosomal enzymes to the the increased intracellular concentration of ␣-(l)-iduronidase in C6 glioma cells incubated with SN6 conditioned brain.
In spite of relevant clinical and basic experimentation media (Table 2) .
on the utilisation of BMT for the treatment of lysosomal storage diseases in which there is significant neurological Is the level of CI-M6P-R regulated by C6 glioma cell growth and cell cycle stage? involvement, like Hurler disease, little is known about the specific capacity of neuronal and glial cells to take The level of expression of the CI-M6P-R on the plasma membrane and in the cytoplasm was also analysed by up individual lysosomal enzymes from the extracellular medium. Thus, our aim was to characterise a series of flow cytometry of C6 and Neuro2A cells before and after induction of cell differentiation and growth arrest by trebasic parameters related to the capacity of neurons and glial cells to take up extracellular ␣-(l)-iduronidase. ating cultures for 4 days with 5 m retinoic acid and low serum medium (1%) (Figure 6 ). Upon differentiation C6
These data should be useful in the evaluation of the The severity of lysosomal diseases is known to depend on the levels of residual enzyme activity, with the most severe diseases appearing in early childhood. 34 In the most severe disorders such as Hurler's disease, patients have less than 1% of ␣-(l)-iduronidase. However, patients who have between 1-5% of ␣-(l)-iduronidase enzyme display the less severe Hurler-Scheie phenotype, have fewer soft tissue problems and are devoid of any neurological symptomatology. Thus, in theory if intracellular levels of ␣-(l)-iduronidase in the brain could be brought to approximately 1-2% of normal, it might be possible to prevent the onset of severe neurological symptoms, or at least to halt the progressive neurological deterioration associated with the null phenotype.
In demonstrating a doubling in the intraneuronal and intraglial levels of ␣-(l)-iduronidase following incubation of cells in medium containing high levels of ␣-(l)-iduronidase, we have shown that an appropriate mechanism for lysosomal enzyme uptake is present in these cells. Furthermore, we have also shown that the cells express the CI-M6P-R necessary to take up lysosomal enzymes from the extracellular medium.
The postnatal development of rodent brain ␣-(L)-iduronidase levels
We performed a developmental study of the endogenous levels of ␣-(l)-iduronidase in various rat brain areas to determine whether there is any particular developmental stage or brain area in which ␣-(l)-iduronidase is ␣-(l)-iduronidase, compared to adults, might be needed from very early stages of brain development. Especially in the hippocampus and cerebellum, a postnatal transient peak appears to be coincident with the peak in postnatal synaptogenesis.
Figure 4 Primary cultures of fibroblasts (A-D) and Schwann cells (E,
Importantly, in Hurler's disease, neurological symp- 
fibroblast has a larger nucleus than those cells labelled as Schwann cells,
Using specific rabbit polyclonal antibodies raised against and also has a different pattern of staining when immunoreacted with purified CI-M6P-R, 35 distinctive and cell type-specific
anti-CI-M6P-R antibodies (G), which in Schwann cells produced a diffuse
immunoreactivity was observed in all cells examined.
stain compared to the strong punctate pattern observed in fibroblasts (G;
In primary cultures of neurons, the immunoreactivity of CI-M6P-R was stronger and more distinct in neurons examined at short intervals after plating, compared with the pattern found after neurons had been cultured 6 days in vitro. During this time, the immunoreactivity Table 2 The effect of mannose-, and glucose-6-phosphate on ␣-(l)-iduronidase uptake into glioma cells C6 cells were maintained in normal growth medium (C6), medium containing 5 mm M6P (C6 + M6P), medium containing 5 mm (glucose 6-phosphate; C6 + G6P), SN6 conditioned medium (C6 + SN6), SN6-conditioned medium containing 5 mm M6P (C6 + SN6 + M6P) or SN6-conditioned medium containing 5 mm G6P (C6 + SN6 + G6P), for 5 days. After this time the cells were harvested and assayed for ␣-(l)-iduronidase activity. The levels of ␣-(l)-iduronidase are given as mol/g/h. Statistically significant differences from controls as determined by the Student's t test are shown in the Table as 
Figure 6 Analysis by flow cytometry of the expression of the CI-M6P-R on the cellular surface (s-M6P-R) and in the cytoplasm (c-M6P-R) in the cell lines C6 (a-f) and Neuro2A (g-l). (a and d) Negative controls of C6 cells for membrane and intracytoplasmic immunostaining, respectively. C6 cells were analysed before (b and e) and after (c and f) differentiation and growth arrest for expression of s-M6P-R (b and c) and c-M6P-R (e and f). (g and j) Nonspecific controls of Neuro2A cells for membrane and intracytoplasmic immunofluorescence, respectively. Neuro2A cells were also analysed before (h and k) and after (i and l) differentiation and growth arrest for expression of s-M6P-R (h and i) and c-M6P-R (k and l). Range bars to detect specific cellular immunoreactivity were set as to include р2% of positive cells when normal rabbit serum was used instead of primary rabbit antiserum raised against the CI-M6P-R; thus, our range bars will exclude у98% of nonspecifically stained cells.
decreased, and became distributed in a polarized fashion anatomical, biochemical and functional polarity. A similar polarized distribution was detected in the neuronal within neuronal somata. We have previously shown that the neocortical neurons in our primary cultures become cell line, Neuro2A. In primary cultures of glial cells, immunoreactivity polarized between 24-72 h after plating. [36] [37] [38] Thus, CI-M6P-R immunoreactive structures in neurons, also appeared like a coarse cytoplasmic pattern distributed homogeneously throughout the cell, while it did appear appear to adopt a polarized distribution, coincidental with neurons becoming postmitotic and establishing their polarized in C6 glioma cells. Fibroblasts also showed a very strong pattern of CI-M6P-R immunoreactivity disthe peripheral nervous system, which would thus become the proper targets in the leukodystrophies. 38, 46 tributed throughout the cytoplasm, while in Schwann cells the immunoreactivity appeared to be much lower. In our primary cultures glial cells and fibroblasts conRetrovirally transduced fibroblasts as a platform cell to provide ␣-(L)-iduronidase to neuronal cells tinue to divide, while Schwann cells and neurons stop dividing soon after plating; thus the pattern and level of Clinically, BMT for the treatment of inherited metabolic disorders has been shown to be most effective as a treat-CI-M6P-R immunoreactivity appears to depend on cell type, and whether cells keep dividing in vitro. ment for symptoms due to the dysfunction of organs other than the nervous system. However, current eviThus, our data correlate well with previous literature data reporting the presence of the CI-M6P-R/insulin dence suggests that if BMT can be performed early enough, ie before functional deterioration has progressed growth factor II (IGFII) receptor in the brain. 39 Most studies performed biochemical, 40, 41 or in situ hybridization too far and before large lesions are visible to modern brain imaging techniques such as nuclear magnetic imagstudies, 42, 43 which, while demonstrating the existence of this receptor in neurons do not allow the cellular identiing, then it can be effective in stabilising the neurological deterioration and slowing further declines in intellectual fication of structures containing these receptors. 42 However, some studies have used immunocytochemical functioning. 9 There are two possible ways in which transplantation could help to deliver the missing lysosomal analysis to demonstrate the existence of CI-M6P-R/IGFII receptor in neurons in vivo 44 and in vitro. 45 Interestingly, enzymes to the brain cells: either transduced cells releasing the missing lysosomal enzyme could be transplanted the study of Couce et al 44 demonstrates an almost exclusive immunostaining of hippocampal neurons, while the directly to the brain; 47-49 or patient's own transduced bone marrow could be self-transplanted into the study of Ocrant et al 45 demonstrates a much higher immunoreactivity of astrocytes when compared to hypopatients. 5, 31, 50, 51 In this case the transplanted bone marrow would give rise to macrophages that could cross the thalamic neurons in vitro. Unfortunately, these studies did not show high magnifications of their immunoreacblood-brain barrier to enter the brain to become microglia and thus release lysosomal enzymes to the CNS tivity throughout the brain; thus, although our data compare well with those of Ocrant et al 45 it is difficult to disextracellular medium. 15, 24, 25, 32, 52 However, either method will rely on the capacity of the target cells, neurons and cern why their and our studies differ from Couce et al 44 who mainly described a strong staining within hippoglia, to take up the lysosomal enzyme released. Thus, we sought to determine whether neurons and glial cells were campal neurons. Whether these differences are due to differences in antibodies, immunocytochemical methods, able to take up ␣-(l)-iduronidase that had been released by retrovirally transduced cells. age of the animals, or brain areas studied in detail, remains to be determined. A clarification of this issue will After incubation with conditioned media, the concentration of ␣-(l)-iduronidase increased to twice the basal be important, since the putative uptake of lysosomal enzymes by diseased brain cells will be accomplished levels in primary glial and neuronal cells, as well as in C6 glioma cells; the uptake into Neuro2A cells was close through this receptor system.
Utilising quantitative methods of assessment (flow to 10 times the basal levels. Levels of endogenous ␣-(l)-iduronidase were 23-24 times higher in glial cells than cytometry), we observed that the levels of CI-M6P-R in C6, but not Neuro2A cells, is reduced upon serum withneurons, which could explain why neurons are mostly affected by the disease-induced decrease in intracellular drawal and treatment with retinoic acid. This treatment allows cells to enter G 0 , exit the normal progression ␣-(l)-iduronidase levels. However, all cell types examined were able to take up ␣-(l)-iduronidase from the through the cell cycle, and differentiate. Upon differentiation both cells change their morphology and biochemimedium. C6, primary glia and neurons, took up between two and three times their basal values, while Neuro2A cal composition. Interestingly, the level of CI-M6P-R was reduced during cell differentiation of the glial cell line, cells took up seven to 14 times their basal levels. This suggests that lysosomes are normally not saturated with but not the neuronal cell line. If similar changes were to occur in the brain in vivo, this would have an important lysosomal enzymes, and that a residual capacity exists to take up lysosomal enzymes from the extracellular milieu. bearing on the use of BMT for the treatment of neurological symptoms in lysosomal diseases, since a reduction in However, these values would have been much higher if, instead of using normal cells we had utilised a transgenic the level of CI-M6P-R would lead to a reduction in the capacity of such glial cells to internalise extracellular model knocked out for the ␣-(l)-iduronidase encoding gene. The fact that even in cells with a normal complysosomal enzymes. Also, the decrease of CI-M6P-R upon differentiation of glial cells might help to explain the lement of lysosomal ␣-(l)-iduronidase the level could be doubled, shows that the percentage increase compared to developmental decrease of ␣-l-iduronidase in the brain in vivo. It appears that upon differentiation, the levels of control cells without any ␣-(l)-iduronidase, would have been much higher. CI-M6P-R decrease; this could be an indication of a generalized reduction of lysosomal markers, leading to a Specific and nonspecific uptake mechanisms could account for the increase in intracellular ␣-(l)-iduronidase decrease in lysosomal enzymes.
We have thus shown that different brain cell types that levels, after incubation in the presence of a conditioned medium containing very high levels of this enzyme. Our are targets for enzyme replacement in lysosomal deficiency disorders, do contain the CI-M6P-R. Neurons experiments utilising an excess of M6P demonstrated that the uptake into the target cells was mediated by the CIare bona fide cellular targets in mucopolysaccharidoses such as Hurler's and MPSVII, which affect mainly neu-M6P-R, since free M6P, but not the structural analogue glucose-6-phosphate, was able to completely block the ronal structure and function. In leukodystrophies the accumulation of unmetabolized intracellular degradation uptake of ␣-(l)-iduronidase enzyme from the surrounding incubation medium. products occurs mainly in glial cells, both in the CNS and
In conclusion, BMT is the single documented treatment USA). Cell-free retroviral supernatant from this cell line was used to infect NIH3T3 cells as described by Fairable to achieve a successful reversion of liver, spleen, connective tissue, and haematopoietic system pathology in bairn & Spooncer. 53 3T3 cells expressing the neomycinphosphotransferase gene were selected by culture in many mucopolysaccharidoses and/or other lysosomal inherited diseases, including Hurler's disease. However, DMEM/10% NBCS supplemented with 500 g/ml G418 (Gibco, Paisley, UK). After 2 weeks of selection, G418-there is still much debate on the effectiveness of BMT to treat the neurological component of such diseases. Such resistant colonies were harvested by trypsinisation, expanded in DMEM/NBCS/G418 and assayed for ␣-(l)-a treatment would only work if brain cells can take up exogenously provided lysosomal enzymes. In this study iduronidase activity. Subsequently one cell line, 3T3LidSN6 (SN6), which expressed the highest levels of we have shown that neurons and glial cells, do indeed contain the necessary cellular machinery to take up ␣-(l)-␣-(l)-iduronidase was chosen for further study (Figure 7b ). iduronidase enzyme from the surrounding medium, and, indeed do take up substantial amounts of lysosomal enzymes provided in the surrounding incubation Developmental study Cortex, cerebellum, striatum and hippocampus were dismedium.
sected from the brains of Wistar rats at developmental stages ranging from E20 to adults; embryonic day 1 (E1)
Materials and methods
was taken to be the day when plugs appeared in the mothers. The tissue was assayed for ␣-(l)-iduronidase Production of retrovirally transduced cell lines activity as described below; tissue samples were hom-A retroviral producer cell line, PALidSN-7, which ogenised and sonicated on ice before assaying the superreleases a replication defective retrovirus encoding natants. Data were analysed by the one-way analysis of human ␣-l-iduronidase and the neomycin phosphovariance (ANOVA) followed by Tukey-Kramer multiple transferase gene (Figure 7a ), which confers resistance to comparisons test using a computer program (Instat, G418 was obtained from D Anson, Women and ChilGraphPad Software, San Diego, CA, USA). Statistically dren's Hospital, Adelaide, Australia. 30 The producer cell significant differences were considered to be at P values line was grown and maintained in DMEM containing of less than 0.05. 10% newborn calf serum (NBCS; Flow Laboratories,
Cells
The neuroblastoma cell line, Neuro2A, and the rat glioma cell line, C6, were obtained from ECACC (Salisbury, UK), and were maintained in DMEM supplemented with 10% horse serum (APP), 5% fetal calf serum (APP, West Midlands, UK), 1% nonessential amino acids (Sigma, Dorset, UK), 1% penicillin/streptomycin (Sigma) and 1% glutamine (Sigma). The primary cultures of astroglial cells, Schwann cells, and neurons were prepared as described in Refs 36, 54-57.
Co-cultures
The SN6 cell line was grown in six-well plates in 1 ml of medium. All other cell types were grown on poly-llysine treated, wax dotted glass coverslips. When the 3T3 cells became 70% confluent the target cells were inverted over them, separated by the distance of the wax dots. This was taken to be experimental day 0. Samples of both medium and cells were taken from these co-cultures on days 1-3. All cell samples were washed twice in 0.1 m phosphate buffered saline (PBS) before being scraped into 1 ml PBS. These cell samples were then pelleted by centrifugation, 250 g for 5 min, the supernatant was removed, and ␣-(l)-iduronidase activity was measured. Immunostained cells were examined using an Olympus Vanox microscope (Tokyo, Japan) and photographed media was assayed as described by Stirling et al, 58 using 4-methylumbelliferyl-␣-l-iduronide (Calbiochem, Notusing Fuji 1600 colour film (Tokyo, Japan) and Kodak 3200 black and white film (Liverpool, UK). tingham, UK) as the substrate. Cell pellets were resuspended in 80-240 l of distilled water containing 0.1% Triton X-100, and disrupted by five cycles of freeze-thaw-␣-(L)-Iduronidase uptake over time C6 cells were grown in six-well plates as described preing. Supernatants obtained after centrifugation were used for enzyme assay. Culture media were also assayed viously in the transfer experiments. On experimental day 0, 1 ml of SN6-conditioned medium was transferred on directly, without any further processing.
All cell samples were washed twice in 0.1 m PBS before to the C6 cells, this medium transfer was repeated on day 3 in order to prevent cell death due to acidic metabolites. being scraped into 1 ml PBS. These cell samples were then pelleted by centrifugation, 250 g for 5 min, and the On day 6 the cells were harvested and assayed for ␣-(l)-iduronidase as above. supernatant was removed. The media (␣-(l)-iduronidase activity released) and cell pellets (␣-(l)-iduronidase produced in SN6 cells, or ␣-(l)-iduronidase taken up by tar-
The effects of mannose-and glucose-6-phosphate on ␣-(L)-iduronidase uptake get cells) were stored frozen until being assayed. Before scraping the target cells, these were washed several times Cells were grown as described in the transfer experiment above. On day 0, SN6-conditioned medium was added in nonconditioned medium and PBS to remove any ␣-(l)-iduronidase which could have become nonspecifically to the cells, either alone or in the presence of 5 mm M6P or glucose-6-phosphate. [59] [60] [61] Medium was replenished on associated with the cells during these experiments.
Twenty microliters of sample were incubated with day 3 and the cells were harvested on day 5 for ␣-(l)-iduronidase assay. 20 l of 2 mm substrate in 0.4 m formate buffer pH 3.5, containing 155 mm NaCl, for 0.5-4 h at 37°C. Reactions were terminated by the addition of 2 ml 0.2 m carbonate C6 and Neuro2A growth arrest experiment C6 cells were grown on poly-l-lysine coated glass buffer pH 9.5 and the fluorescence generated, was measured using an LS2-B fluorimeter (Perkin-Elmer).
coverslips in 2 ml of either complete medium (15% serum), or low serum medium (1%) and 5 m retinoic acid, in the latter case to induce growth arrest and differImmunocytochemistry and fluorescence microscopy Neuronal and glial cells were grown on poly-l-lysine entiation. [62] [63] [64] Four days later the cells were used for immunocytochemical studies using the M6PR antibody (Sigma) coated glass coverslips in six-well plates. At the time of the immunocytochemical experiment, cells were as described above. Immunoreactivity for the CI-M6P-R was assessed for cells grown under both growth conwashed briefly in PBS to remove excess medium, and fixed in 4% paraformaldehyde, 0.12 m sucrose in PBS ditions and the number of differentiated cells which scored positive for CI-M6P-R was determined and compH 7.4 for 20 min. The cells were then washed four times in PBS and permeabilised with 0.1% Triton X-100 (BDH, pared to the percentage of positive cells in the undifferentiated condition. Student's t tests were carried out using Dorset, UK) in PBS for 5 min after which they were washed further in PBS, incubated in 50 mm NH 4 Cl for the SigmaPlot Computer package. 10 min, washed again in PBS, and then incubated for 1 h in 10% normal swine serum (NSwS; Vector Laboratories, Flow cytometry analysis We performed our assays in such a way as to detect the Peterborough, UK) in PBS. Thereafter, cells were washed once in 1% NSwS in PBS, incubated in primary antibody immunoreactivity for the CI-M6P-R both on the cell membrane and intracytoplasmic under separate confor 2-4 h, washed six times in 1% NSwS in PBS, and finally incubated in secondary antibodies (Jackson Labs, ditions. For the detection of cell surface expression of the CI-M6P-R on C6 and Neuro2A cells, these were detached USA) for a further 2-4 h. Following this the cells were given several final washes in PBS, incubated in 4Ј, 6-from plastic using a cell scraper and then successively incubated with: (a) polyclonal rabbit anti CI-M6P-R at diamidino-2-phenylindole (DAPI), to label nuclei for 10 min, washed with one brief dip in distilled water and 1:200 for 2 h; and (b) donkey F(abЈ) 2 anti-rabbit IgG fluorescein isothyocianate (FITC) conjugated (Jackson mounted in Mowiol (Calbiochem) on to glass slides. 38, 57 The primary antibodies used in this work were diluted Laboratories, Bedford, UK) for 45 min. All incubations and washing steps were done at 4°C with DMEM supin 1% NSwS in PBS, and were the following: monoclonal mouse recognising MAP-2, 1:200 (Sigma); monoclonal plemented with 5% FCS and 0.1% Na 3 N in order to prevent internalisation of the CI-M6P-R from the cell surface. mouse recognising GFAP, 1:200 (Sigma); monoclonal mouse recognising Thy 1.1, 1:100 (Sigma); monoclonal Cells labeled with normal rabbit serum (1:200) and
